Not Medical Advice, Tho™

A 2,000-word titration protocol with sources, spreadsheets, and a praying-hands emoji disclaimer load-bearing the entire post.

Filed under Survodutide ·Eloralintide ·Semax · #cope ·#discord ·#not-medical-advice

Active Compounds

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

Eloralintide · Amylin Receptor Agonist

Eli Lilly's once-weekly selective amylin receptor agonist. Phase 2 trials showed up to 20% weight loss at 48 weeks with favorable tolerability. Phase 3 enrollment began late 2025.

Semax · Nootropic Peptide

A synthetic peptide analog of ACTH(4-10) developed in Russia, studied for cognitive enhancement and neuroprotection.

RX: Survodutide · Eloralintide · Semax
Dosage: one (1) 🙏 emoji
Half-life: until the mods delete the thread
Source: manual
Tags: cope , discord , not-medical-advice
Stamped: 2026-06-24 · Cycle 025
Lot #: LOT-20260624T11:08:17.731Z